Tag: Phase
One-Day Cup: Hampshire, Gloucestershire and Worcestershire attain knockout part
Joe Weatherley (pictured) singled out Ian Holland among his praise for Hampshire's bowlers after their win over SurreyHampshire made it six wins out...
Promising tumor control for fostrox in combination with Lenvima in ongoing...
Continued tumor control in the liver in 7 of the first 10 patients after three months of treatmentThe patient who benefited the longest...
Bio-Thera Solutions Announces Positive Phase 1 Clinical Data for BAT8006 (Folate…...
GUANGZHOU, China, Aug. 12, 2023 /PRNewswire/ -- Bio-Thera Solutions, Ltd (688177:SH), a commercial-stage biopharmaceutical company developing a pipeline of innovative assets and biosimilars,...
Bio-Thera Solutions Announces Positive Phase 1 Clinical Data for BAT8006 (Folate…...
GUANGZHOU, China, Aug. 12, 2023 /PRNewswire/ -- Bio-Thera Solutions, Ltd (688177:SH), a commercial-stage biopharmaceutical company developing a pipeline of innovative assets and biosimilars,...
Novartis remibrutinib Phase III trials met their primary endpoints and showed...
Ad hoc announcement pursuant to Art. 53 LRThe Phase III REMIX-1 and REMIX-2 studies met all primary and secondary endpoints, showing rapid, clinically...
Bavarian Nordic Reports Positive Phase 3 Topline Results for Chikungunya Virus...
Chikungunya vaccine candidate met all the co-primary endpoints of the Phase 3 study and was shown to be highly immunogenic in the majority...
Biosion Announces Phase II Study Start for Anti-TSLP mAb BSI-045B in...
NEWARK, N.J. and NANJING, China, July 31, 2023 /PRNewswire/ -- Biosion USA, Inc. (Biosion), a global clinical-stage R&D biotechnology company, today announced the phase 2...
Ecopol Announces Partnership with SK Capital to Drive Next Phase of...
SK Capital to support Ecopol's rapid growth as the Company expands its production footprint into the U.S. to best serve its global customer...
ENB Therapeutics Presents Top-line Results from Phase 1b ENBOLDEN-101 Study in...
ENB is developing first in class small molecule ENB-003 to selectively targeting the ETB receptor - a novel immune checkpoint
The ENB-003 in combination...
Calliditas announces supportive interim data from Phase 2 head and neck...
STOCKHOLM, July 13, 2023 /PRNewswire/ -- Calliditas Therapeutics AB CALT (NASDAQ Stockholm: CALTX) ("Calliditas") today announced interim data from the proof-of-concept Phase 2...